Review

lentiviral constructs of ptar shrna (Biowit Technologies)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Biowit Technologies lentiviral constructs of ptar shrna

The identification of a ceRNA network for mesenchymal OvCa. a The ceRNA network in mesenchymal OvCa. Rounded rectangles, ellipses and hexagons denote lncRNAs, EMT genes and miRNAs, respectively. Up-regulated lncRNAs, EMT genes and miRNAs are shown in red and down-regulated lncRNAs, EMT genes and miRNAs are shown in green. b ZEB1 was significantly up-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set. c Positive correlation between <t>PTAR</t> and ZEB1 expression in the TCGA data set. d The lncRNA PTAR was significantly up-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set. e Nagative correlation between miR-101 and ZEB1 expression in the TCGA data set. f Nagetive correlation between PTAR and miR-101 expression in the TCGA data set. g miR-101 was significantly down-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set

Lentiviral Constructs Of Ptar Shrna, supplied by Biowit Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shrna+constructs/lentiviral+constructs+of+ptar+shrna/pmc06087007-71-4-9
Average 90 stars, based on 1 article reviews

lentiviral constructs of ptar shrna - by Bioz Stars, 2026-10

90/100 stars

Images

1) Product Images from "LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression"

Article Title: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression

Journal: Molecular Cancer

doi: 10.1186/s12943-018-0870-5

Figure Legend Snippet: The identification of a ceRNA network for mesenchymal OvCa. a The ceRNA network in mesenchymal OvCa. Rounded rectangles, ellipses and hexagons denote lncRNAs, EMT genes and miRNAs, respectively. Up-regulated lncRNAs, EMT genes and miRNAs are shown in red and down-regulated lncRNAs, EMT genes and miRNAs are shown in green. b ZEB1 was significantly up-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set. c Positive correlation between PTAR and ZEB1 expression in the TCGA data set. d The lncRNA PTAR was significantly up-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set. e Nagative correlation between miR-101 and ZEB1 expression in the TCGA data set. f Nagetive correlation between PTAR and miR-101 expression in the TCGA data set. g miR-101 was significantly down-regulated in mesenchymal OvCa compared with epithelial OvCa in the TCGA data set

Techniques Used: Expressing

Knockdown of lncRNA PTAR inhibits tumor progression in an orthotopic mouse model of OvCa. a The macroscopic observation of the size and range of metastatic lesions in nude mice. b Representative images of tumors from nude mice bearing xenograft tumors with SKOV3 cells infected with a lentivirus carrying a short hairpin RNA against PTAR (lenti-sh-PTAR) or its scramble negative control (lenti-sh-Scramble). c , d The average number of metastatic nodules and tumor xenograft weights in nude mice. n = 11–13. * P < 0.05. e An immunohistochemistry assay was applied to determine the expression of E-cadherin, fibronectin 1 (FN1), zinc finger E-box binding homeobox 1 (ZEB1) and vimentin in a cell-derived xenograft tumor model. f , g The expression of epithelial-mesenchymal transition (EMT) relevant markers, including E-cadherin, vimentin, FN1 and ZEB1 in tissues derived from xenograft tumors, as determined by qRT-PCR and western blot, respectively. n = 6. * P < 0.05

Figure Legend Snippet: Knockdown of lncRNA PTAR inhibits tumor progression in an orthotopic mouse model of OvCa. a The macroscopic observation of the size and range of metastatic lesions in nude mice. b Representative images of tumors from nude mice bearing xenograft tumors with SKOV3 cells infected with a lentivirus carrying a short hairpin RNA against PTAR (lenti-sh-PTAR) or its scramble negative control (lenti-sh-Scramble). c , d The average number of metastatic nodules and tumor xenograft weights in nude mice. n = 11–13. * P < 0.05. e An immunohistochemistry assay was applied to determine the expression of E-cadherin, fibronectin 1 (FN1), zinc finger E-box binding homeobox 1 (ZEB1) and vimentin in a cell-derived xenograft tumor model. f , g The expression of epithelial-mesenchymal transition (EMT) relevant markers, including E-cadherin, vimentin, FN1 and ZEB1 in tissues derived from xenograft tumors, as determined by qRT-PCR and western blot, respectively. n = 6. * P < 0.05

Techniques Used: Knockdown, Infection, shRNA, Negative Control, Immunohistochemistry, Expressing, Binding Assay, Derivative Assay, Quantitative RT-PCR, Western Blot

PTAR promotes EMT and metastasis through the modulation of miR-101/ZEB1. The SKOV3, A2780 and OVCAR3 cells were transfected with PTAR plasmid with or without miR-101 mimic. a, b Wound healing assays showing cell migration in SKOV3 and A2780 cells. n = 4, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. c , d Migration assays in SKOV3 and A2780 cells, respectively. e The invasiveness of SKOV3 cells was determined by an invasion assay using matrigel transwell chambers. n = 4, ** p < 0.01. f The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in SKOV3 cells. n = 5, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. g The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in A2780 cells. n = 5, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. h The protein levels of E-cadherin and ZEB1 in OVCAR3 cells. n = 3, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR

Figure Legend Snippet: PTAR promotes EMT and metastasis through the modulation of miR-101/ZEB1. The SKOV3, A2780 and OVCAR3 cells were transfected with PTAR plasmid with or without miR-101 mimic. a, b Wound healing assays showing cell migration in SKOV3 and A2780 cells. n = 4, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. c , d Migration assays in SKOV3 and A2780 cells, respectively. e The invasiveness of SKOV3 cells was determined by an invasion assay using matrigel transwell chambers. n = 4, ** p < 0.01. f The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in SKOV3 cells. n = 5, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. g The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in A2780 cells. n = 5, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR. h The protein levels of E-cadherin and ZEB1 in OVCAR3 cells. n = 3, * P < 0.05 vs. pcDNA3.1, # P < 0.05 vs. PTAR

Techniques Used: Transfection, Plasmid Preparation, Migration, Invasion Assay

Silencing PTAR alleviates ovarian cancer cell tumorigenicity. The SKOV3, A2780 and OVCAR3 cells were transfected with sh-PTAR with or without miR-101 inhibition in the presence or absence of 10 ng/ml TGF-β1 for 48 h. a , b Wound healing assays were performed both in SKOV3 and A2780 cells treated as specified. n = 4, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR. c , d Cell migration in SKOV3 and A2780 cells was determined using transwell chambers. n = 4, ** P < 0.01. e The invasion ability of SKOV3 cells was evaluated using matrigel transwell chambers. n = 4, ** P < 0.01. f , g The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in SKOV3 and A2780 cells. n = 5, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR. h The protein levels of E-cadherin and ZEB1 in OVCAR3 cells. n = 3, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR

Figure Legend Snippet: Silencing PTAR alleviates ovarian cancer cell tumorigenicity. The SKOV3, A2780 and OVCAR3 cells were transfected with sh-PTAR with or without miR-101 inhibition in the presence or absence of 10 ng/ml TGF-β1 for 48 h. a , b Wound healing assays were performed both in SKOV3 and A2780 cells treated as specified. n = 4, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR. c , d Cell migration in SKOV3 and A2780 cells was determined using transwell chambers. n = 4, ** P < 0.01. e The invasion ability of SKOV3 cells was evaluated using matrigel transwell chambers. n = 4, ** P < 0.01. f , g The protein levels of E-cadherin, vimentin, FN1 and ZEB1 in SKOV3 and A2780 cells. n = 5, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR. h The protein levels of E-cadherin and ZEB1 in OVCAR3 cells. n = 3, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1 + sh-Scram, & P < 0.05 vs. TGF-β1 + sh-PTAR

Techniques Used: Transfection, Inhibition, Migration

PTAR negatively regulates miR-101 expression and activity in OvCa cells. a , b The expression of PTAR and miR-101 in SKOV3 and A2780 cells after treatment with 10 ng/ml TGF-β1 for 48 h. c , d Analysis with qRT-PCR was used to assess the expression of PTAR and miR-101 in SKOV3 and A2780 cells in response to PTAR overexpression. e The knockdown efficiency of the sh-PTAR plasmid was confirmed by qRT-PCR analysis. f Expression of miR-101 was detected in OvCa cells in response to PTAR suppression. g The luciferase reporter activity of chimeric vectors carrying the luciferase gene and a fragment of PTAR containing the (WT) binding site or a mutated binding site for miR-101. h , i The luciferase activity of miR-101 sensor in OvCa cells transfected as specified. n = 5. * P < 0.05

Figure Legend Snippet: PTAR negatively regulates miR-101 expression and activity in OvCa cells. a , b The expression of PTAR and miR-101 in SKOV3 and A2780 cells after treatment with 10 ng/ml TGF-β1 for 48 h. c , d Analysis with qRT-PCR was used to assess the expression of PTAR and miR-101 in SKOV3 and A2780 cells in response to PTAR overexpression. e The knockdown efficiency of the sh-PTAR plasmid was confirmed by qRT-PCR analysis. f Expression of miR-101 was detected in OvCa cells in response to PTAR suppression. g The luciferase reporter activity of chimeric vectors carrying the luciferase gene and a fragment of PTAR containing the (WT) binding site or a mutated binding site for miR-101. h , i The luciferase activity of miR-101 sensor in OvCa cells transfected as specified. n = 5. * P < 0.05

Techniques Used: Expressing, Activity Assay, Quantitative RT-PCR, Over Expression, Knockdown, Plasmid Preparation, Luciferase, Binding Assay, Transfection

Overexpression of miR-101 attenuated TGF-β1-induced metastasis in OvCa cell lines. a , b Wound healing assays performed in SKOV3 and A2780 cells, respectively. Images were captured at 0, 24, and 48 h. n = 4, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1. c , d The migration ability of SKOV3 and A2780 cells was determined using transwell assays. n = 4, ** P < 0.01. e The expression levels of epithelial and mesenchymal markers were detected by western blot in SKOV3 cells. n = 5, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1. f Up-regulation of lncRNA PTAR enhanced ZEB1 expression by competitively binding miR-101, which promoted OvCa cell EMT and invasion

Figure Legend Snippet: Overexpression of miR-101 attenuated TGF-β1-induced metastasis in OvCa cell lines. a , b Wound healing assays performed in SKOV3 and A2780 cells, respectively. Images were captured at 0, 24, and 48 h. n = 4, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1. c , d The migration ability of SKOV3 and A2780 cells was determined using transwell assays. n = 4, ** P < 0.01. e The expression levels of epithelial and mesenchymal markers were detected by western blot in SKOV3 cells. n = 5, * P < 0.05 vs. Ctrl, # P < 0.05 vs. TGF-β1. f Up-regulation of lncRNA PTAR enhanced ZEB1 expression by competitively binding miR-101, which promoted OvCa cell EMT and invasion

Techniques Used: Over Expression, Migration, Expressing, Western Blot, Binding Assay

Construct:

Article Title: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression
Article Snippet: Finally, immunoreactivity was detected using the Odyssey Infrared Imaging System (Gene Company Limited, Hong Kong, China). .. The lentiviral constructs of PTAR shRNA were constructed by Biowit Technology (Shenzhen, China). ..

shRNA:

Image Search Results

Significantly differentially expressed ECM molecules in early, mid and late-stage mammary tumor samples from the PyMT mouse model of breast cancer in comparison to healthy fat pad tissue (A) PCA of individual samples ( n = 4 or 5 mice per group). Principal components 1 and 2 account for 81.6% of the variability in the dataset. (B) Heatmap of significantly differentially deposited matrisomal elements between groups within the dataset (left). Missing values are shaded in gray. Four major clusters were identified based on Euclidian hierarchical clustering of proteins (middle) and the matrisome categorical annotation for these clustered matrisomal elements based on the matrisome project is shown (right). Expression of PXDN in each sample (cluster 3) is highlighted in red.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Significantly differentially expressed ECM molecules in early, mid and late-stage mammary tumor samples from the PyMT mouse model of breast cancer in comparison to healthy fat pad tissue (A) PCA of individual samples ( n = 4 or 5 mice per group). Principal components 1 and 2 account for 81.6% of the variability in the dataset. (B) Heatmap of significantly differentially deposited matrisomal elements between groups within the dataset (left). Missing values are shaded in gray. Four major clusters were identified based on Euclidian hierarchical clustering of proteins (middle) and the matrisome categorical annotation for these clustered matrisomal elements based on the matrisome project is shown (right). Expression of PXDN in each sample (cluster 3) is highlighted in red.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Comparison, Expressing

Association of PXDN expression with patient overall survival Significance between Kaplan-Meier survival curves were calculated with the log-rank test. (A) Overall survival of 1,082 patients from the TCGA breast cancer cohort stratified by median mRNA expression of PXDN. (B) Overall survival of 1,082 patients from the TCGA breast cancer cohort separated by disease stage, and stratified by median mRNA expression of PXDN (dotted line = low PXDN expression, solid line = high PXDN expression) and stage of disease (stage I, red; II, gold; III, green; IV, blue; or unknown, purple). (C) Extraction of data from (B) showing patients with stage II breast cancer at the time of diagnosis stratified by median mRNA expression of PXDN (dotted line = low PXDN expression, solid line = high PXDN expression) ( n = 615). (D) Examples of PXDN IHC staining intensity and corresponding intensity scores for the stromal and epithelial compartments of tumors ( n = 334). Scale bars, 50 μm. (E) Overall survival of 311 invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by high vs. low Allred-scores for PXDN IHC staining of epithelial compartments of tumors. (F) Overall survival of 309 invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by high vs. low Allred-scores for PXDN IHC staining of stromal compartments of tumors. (G) Overall survival of invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by combined stromal and epithelial Allred-scores for PXDN IHC staining of cores. Log-rank p values between each curve of (G) are listed in .

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Association of PXDN expression with patient overall survival Significance between Kaplan-Meier survival curves were calculated with the log-rank test. (A) Overall survival of 1,082 patients from the TCGA breast cancer cohort stratified by median mRNA expression of PXDN. (B) Overall survival of 1,082 patients from the TCGA breast cancer cohort separated by disease stage, and stratified by median mRNA expression of PXDN (dotted line = low PXDN expression, solid line = high PXDN expression) and stage of disease (stage I, red; II, gold; III, green; IV, blue; or unknown, purple). (C) Extraction of data from (B) showing patients with stage II breast cancer at the time of diagnosis stratified by median mRNA expression of PXDN (dotted line = low PXDN expression, solid line = high PXDN expression) ( n = 615). (D) Examples of PXDN IHC staining intensity and corresponding intensity scores for the stromal and epithelial compartments of tumors ( n = 334). Scale bars, 50 μm. (E) Overall survival of 311 invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by high vs. low Allred-scores for PXDN IHC staining of epithelial compartments of tumors. (F) Overall survival of 309 invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by high vs. low Allred-scores for PXDN IHC staining of stromal compartments of tumors. (G) Overall survival of invasive ductal carcinoma patients from the CREA tumor microarray cohort stratified by combined stromal and epithelial Allred-scores for PXDN IHC staining of cores. Log-rank p values between each curve of (G) are listed in .

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Expressing, Extraction, Biomarker Discovery, Immunohistochemistry, Microarray

Single cell analysis of breast tumor cells expressing PXDN (A–C) Murine PyMT tumor single cell data (11,490 cells) obtained from Valdés-Mora et al. (A) UMAP of the major cell types identified in the murine single cell data. (B) UMAP of PXDN expression across cells. (C) Violin plots of fold change in PXDN expression according to cell type in the murine dataset. (D and E) Human breast cancer single cell and spatial data containing 130,246 cells from 26 invasive breast cancer patients. (D) UMAP of the major cell types identified in the human single cell data. (E) UMAP of PXDN expression across human cells. (F) Boxplots of fold change in PXDN expression according to cell type in the human dataset.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Single cell analysis of breast tumor cells expressing PXDN (A–C) Murine PyMT tumor single cell data (11,490 cells) obtained from Valdés-Mora et al. (A) UMAP of the major cell types identified in the murine single cell data. (B) UMAP of PXDN expression across cells. (C) Violin plots of fold change in PXDN expression according to cell type in the murine dataset. (D and E) Human breast cancer single cell and spatial data containing 130,246 cells from 26 invasive breast cancer patients. (D) UMAP of the major cell types identified in the human single cell data. (E) UMAP of PXDN expression across human cells. (F) Boxplots of fold change in PXDN expression according to cell type in the human dataset.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Single-cell Analysis, Expressing, Single Cell

PXDN affects cell proliferation and spheroid formation dynamics in CAFs Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are shown on each graph. p values <0.05 were considered significant. ns = not significant. (A and C) RNA expression of PXDN in shScr and sh#1 (A), or WT and OE (C) CAFs. Error bars show the standard deviation of six independent experiments. (B and D) Representative western blots showing PXDN levels in conditioned media (top) from shScr and sh#1 CAFs (B) or WT and OE CAFs (D), with densitometry quantification of three biological replicate western blots (bottom). Densitometry measurements were normalized to total protein loading (measured by Ponceau S stain) and calculated relative to control (shScr or WT) protein expression. (E and F) 2D proliferation of shScr and sh#1 CAFs (E) or WT and OE CAFs (F) as measured by Alamar blue assay five days of culture (left). Differences between CAF lines were directly compared on day 5 (right). Error bars indicate the standard error of the mean for three biological replicates. (G–L) 3D growth of shScr (blue), sh#1 (red), WT (purple), and OE (gold) CAFs as spheroids over the course of 16 days. (G and I) Spheroid area and (K and L) representative images over the course of 16 days. Scale bars, 400 μm. Dotted lines indicate media changes on days 4, 8, and 12. Error bars indicate the standard error of the mean for three biological replicates. (H and J) The day of spheroid growth at which spheroids reached their smallest size before expanding. Error bars indicate the standard error of 24 spheroids across three biological replicates.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: PXDN affects cell proliferation and spheroid formation dynamics in CAFs Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are shown on each graph. p values <0.05 were considered significant. ns = not significant. (A and C) RNA expression of PXDN in shScr and sh#1 (A), or WT and OE (C) CAFs. Error bars show the standard deviation of six independent experiments. (B and D) Representative western blots showing PXDN levels in conditioned media (top) from shScr and sh#1 CAFs (B) or WT and OE CAFs (D), with densitometry quantification of three biological replicate western blots (bottom). Densitometry measurements were normalized to total protein loading (measured by Ponceau S stain) and calculated relative to control (shScr or WT) protein expression. (E and F) 2D proliferation of shScr and sh#1 CAFs (E) or WT and OE CAFs (F) as measured by Alamar blue assay five days of culture (left). Differences between CAF lines were directly compared on day 5 (right). Error bars indicate the standard error of the mean for three biological replicates. (G–L) 3D growth of shScr (blue), sh#1 (red), WT (purple), and OE (gold) CAFs as spheroids over the course of 16 days. (G and I) Spheroid area and (K and L) representative images over the course of 16 days. Scale bars, 400 μm. Dotted lines indicate media changes on days 4, 8, and 12. Error bars indicate the standard error of the mean for three biological replicates. (H and J) The day of spheroid growth at which spheroids reached their smallest size before expanding. Error bars indicate the standard error of 24 spheroids across three biological replicates.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: RNA Expression, Standard Deviation, Western Blot, Staining, Control, Expressing, Alamar Blue Assay

PXDN inhibits the ability of CAFs to remodel collagen matrices (A and C) Representative images of collagen matrices contraction over the course of 12 days when seeded with shScr or sh#1 CAFs (A) or WT or OE CAFs (C). Scale bars, 1 cm. (B and D) Area of matrices during contraction over the course of 12 days (left), with differences in final area of matrices compared at day 12 (right). Error bars indicate the standard error of the mean for three biological replicates. p values were calculated using Student’s t tests. p values <0.05 were considered significant.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: PXDN inhibits the ability of CAFs to remodel collagen matrices (A and C) Representative images of collagen matrices contraction over the course of 12 days when seeded with shScr or sh#1 CAFs (A) or WT or OE CAFs (C). Scale bars, 1 cm. (B and D) Area of matrices during contraction over the course of 12 days (left), with differences in final area of matrices compared at day 12 (right). Error bars indicate the standard error of the mean for three biological replicates. p values were calculated using Student’s t tests. p values <0.05 were considered significant.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques:

Impact of CAF-produced PXDN on cancer cell proliferation and motility Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are indicated on each graph. p values <0.05 were considered significant. ns = not significant. (A) Schematic of generation of CAF-generated CDMs, onto which cancer cells were seeded. (B and C) Proliferation rates of cancer cells seeded on CDMs produced by sh#1 or shScr CAFs (B), or by WT and OE CAFs (C) as measured by Alamar blue at day 7. Error bars represent the standard deviation of eight replicates. (D and F) Mean velocity of cancer cells when seeded onto CDMs produced by shScr or sh#1 CAFs (D) or by WT or OE CAFs (F). (E and G) Distance traveled by cancer cells when seeded onto CDMs produced by shScr or sh#1 CAFs (E) or by WT or OE CAFs (G). A minimum of ten cells were tracked per biological replicate, across three biological replicates. Error bars indicate the standard deviation.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Impact of CAF-produced PXDN on cancer cell proliferation and motility Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are indicated on each graph. p values <0.05 were considered significant. ns = not significant. (A) Schematic of generation of CAF-generated CDMs, onto which cancer cells were seeded. (B and C) Proliferation rates of cancer cells seeded on CDMs produced by sh#1 or shScr CAFs (B), or by WT and OE CAFs (C) as measured by Alamar blue at day 7. Error bars represent the standard deviation of eight replicates. (D and F) Mean velocity of cancer cells when seeded onto CDMs produced by shScr or sh#1 CAFs (D) or by WT or OE CAFs (F). (E and G) Distance traveled by cancer cells when seeded onto CDMs produced by shScr or sh#1 CAFs (E) or by WT or OE CAFs (G). A minimum of ten cells were tracked per biological replicate, across three biological replicates. Error bars indicate the standard deviation.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Produced, Generated, Standard Deviation

Effect of CAF PXDN expression on breast tumor progression in vivo Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are indicated on each graph. p values <0.05 were considered significant; ns = not significant. (A and B) Latency of tumor formation from the time cells were implanted into mice along with shScr or sh#1 CAFs (A) or with WT or OE CAFs (B) until tumors reached 50 mm 3 in size. (C and D) Final weights of tumors upon collection from mice implanted with cancer cells and shScr or sh#1 CAFs (C) or with WT or OE CAFs (D). (E) Representative images of α-SMA staining in tumors from shScr or sh#1 CAF tumors. Scale bars, 100 μm. (F) Quantification of α-SMA staining in shScr and sh#1 CAF tumors. Error bars indicate the standard deviation. (G) Representative images of α-SMA staining in tumors from WT or OE CAF tumors. Scale bars, 100 μm. (H) Quantification of α-SMA staining in WT and OE CAF tumors. Error bars indicate the standard deviation.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Effect of CAF PXDN expression on breast tumor progression in vivo Differences between shScr CAFs and sh#1 CAFs, or between WT CAFs and OE CAFs, were calculated using Student’s t tests and p values are indicated on each graph. p values <0.05 were considered significant; ns = not significant. (A and B) Latency of tumor formation from the time cells were implanted into mice along with shScr or sh#1 CAFs (A) or with WT or OE CAFs (B) until tumors reached 50 mm 3 in size. (C and D) Final weights of tumors upon collection from mice implanted with cancer cells and shScr or sh#1 CAFs (C) or with WT or OE CAFs (D). (E) Representative images of α-SMA staining in tumors from shScr or sh#1 CAF tumors. Scale bars, 100 μm. (F) Quantification of α-SMA staining in shScr and sh#1 CAF tumors. Error bars indicate the standard deviation. (G) Representative images of α-SMA staining in tumors from WT or OE CAF tumors. Scale bars, 100 μm. (H) Quantification of α-SMA staining in WT and OE CAF tumors. Error bars indicate the standard deviation.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Expressing, In Vivo, Staining, Standard Deviation

Effect of PXDN inhibition on breast tumor progression using AZD5904 (A) Inhibition of PXDN by a range of concentrations of AZD5904 measured on live cells using a modified Amplex red activity assay. Resorufin fluorescence was monitored continuously for 1 h. Error bars indicate standard error of the mean across three biological replicates, each consisting of eight technical replicates. (B) Final resorufin fluorescence readings at 60 min were used to determine to IC50 inhibitory concentration of AZD5904. (C) Kaplan-Meier curve of mouse survival measured from the start of treatment with AZD5904 or vehicle (when tumors reached a detectable size of 50 mm 3 ) until tumors reached a maximum ethical size of 1 cm by 1 cm and mice were sacrificed. Survival curves were significantly different, with a log-rank p value of 0.0088. (D) Final weights of tumors upon collection from mice in the AZD5904 in vivo study. Error bars indicate the standard deviation. Student’s t test showed no statistical significance between vehicle and AZD5904 treatment groups. (E) Time taken for tumors to reach the detectable size of 50 mm 3 at which point treatment started. Error bars indicate the standard deviation. Student’s t test showed no statistical significance between vehicle and AZD5904 treatment groups.

Journal: iScience

Article Title: Stromal peroxidasin drives early tumor growth in breast cancer

doi: 10.1016/j.isci.2026.116078

Figure Lengend Snippet: Effect of PXDN inhibition on breast tumor progression using AZD5904 (A) Inhibition of PXDN by a range of concentrations of AZD5904 measured on live cells using a modified Amplex red activity assay. Resorufin fluorescence was monitored continuously for 1 h. Error bars indicate standard error of the mean across three biological replicates, each consisting of eight technical replicates. (B) Final resorufin fluorescence readings at 60 min were used to determine to IC50 inhibitory concentration of AZD5904. (C) Kaplan-Meier curve of mouse survival measured from the start of treatment with AZD5904 or vehicle (when tumors reached a detectable size of 50 mm 3 ) until tumors reached a maximum ethical size of 1 cm by 1 cm and mice were sacrificed. Survival curves were significantly different, with a log-rank p value of 0.0088. (D) Final weights of tumors upon collection from mice in the AZD5904 in vivo study. Error bars indicate the standard deviation. Student’s t test showed no statistical significance between vehicle and AZD5904 treatment groups. (E) Time taken for tumors to reach the detectable size of 50 mm 3 at which point treatment started. Error bars indicate the standard deviation. Student’s t test showed no statistical significance between vehicle and AZD5904 treatment groups.

Article Snippet: Lentiviral PXDN shRNA knockdown constructs and a Scrambled control construct containing GFP sequences were obtained from OriGene (TL513178V).

Techniques: Inhibition, Modification, Activity Assay, Fluorescence, Concentration Assay, In Vivo, Standard Deviation

( A ) Relative SHP-1 protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) Relative SHP-1 protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing

( A ) SHP-1 protein expression in bladder tissue was significantly lower in muscle-invasive (MI, n = 8) tumor than in non-muscle-invasive (NMI, n = 8) and urothelial tissue with no residual disease (NRD, n = 10). ( B ) Examples of DAB and corresponding H&E staining in the bladder tissues examined in this study. The error bars represent the interquartile range.

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) SHP-1 protein expression in bladder tissue was significantly lower in muscle-invasive (MI, n = 8) tumor than in non-muscle-invasive (NMI, n = 8) and urothelial tissue with no residual disease (NRD, n = 10). ( B ) Examples of DAB and corresponding H&E staining in the bladder tissues examined in this study. The error bars represent the interquartile range.

Techniques: Expressing, Staining

Correlation plots (n = 19) of SHP-1 protein expression with the EMT markers E-cadherin, N-cadherin, and Vimentin. Gray areas represent the 95%CI. Representative Western blot images: from the BCa cell lines EJ and HT-1376, the first lane of each pair corresponds to the protein indicated above each lane, and the second corresponds to the total protein detected for the same lane.

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Correlation plots (n = 19) of SHP-1 protein expression with the EMT markers E-cadherin, N-cadherin, and Vimentin. Gray areas represent the 95%CI. Representative Western blot images: from the BCa cell lines EJ and HT-1376, the first lane of each pair corresponds to the protein indicated above each lane, and the second corresponds to the total protein detected for the same lane.

Techniques: Expressing, Western Blot

( A ) SHP-1 protein expression following transduction with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 6, RT-112 n = 7, TCCSUP n = 4, UM-UC-3 n = 6. ( B ) Representative Western blot images: the first lane of each pair corresponds to SHP-1, and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM. ( C ) Relative proliferation rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 5, TCCSUP n = 9, UM-UC-3 n = 5. Error bars represent the SEM.

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) SHP-1 protein expression following transduction with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 6, RT-112 n = 7, TCCSUP n = 4, UM-UC-3 n = 6. ( B ) Representative Western blot images: the first lane of each pair corresponds to SHP-1, and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM. ( C ) Relative proliferation rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 5, TCCSUP n = 9, UM-UC-3 n = 5. Error bars represent the SEM.

Techniques: Expressing, Transduction, shRNA, Western Blot

( A ) Relative migration rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 4, TCCSUP n = 3, UM-UC-3 n = 3. ( B ) Representative images from in vitro migration assays (scale bar = 200 μm). ( C ) Relative invasion rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 3, RT-112 n = 5, TCCSUP n = 3, UM-UC-3 n = 3. ( D ) Representative images from in vitro invasion assays (scale bar = 200 μm). Error bars represent the SEM.

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) Relative migration rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 4, TCCSUP n = 3, UM-UC-3 n = 3. ( B ) Representative images from in vitro migration assays (scale bar = 200 μm). ( C ) Relative invasion rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 3, RT-112 n = 5, TCCSUP n = 3, UM-UC-3 n = 3. ( D ) Representative images from in vitro invasion assays (scale bar = 200 μm). Error bars represent the SEM.

Techniques: Migration, Transduction, shRNA, In Vitro

Significant gene sets resulting from GSEA of RNA sequence data comparing the transduced BCa lines with high-SHP-1-expressing lines versus low-SHP-1-expressing lines (q-value < 0.1).

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Significant gene sets resulting from GSEA of RNA sequence data comparing the transduced BCa lines with high-SHP-1-expressing lines versus low-SHP-1-expressing lines (q-value < 0.1).

Techniques: Sequencing, Expressing

Relative expression of pAkt/Akt in BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): RT-112 n = 7 and TCCSUP n = 8. Representative Western blot images: the first lane of each pair corresponds to Akt or pAkt (ser473), and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM.

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Relative expression of pAkt/Akt in BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): RT-112 n = 7 and TCCSUP n = 8. Representative Western blot images: the first lane of each pair corresponds to Akt or pAkt (ser473), and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM.

Techniques: Expressing, Transduction, shRNA, Western Blot

Review

lentiviral constructs of ptar shrna (Biowit Technologies)

Structured Review

Images

1) Product Images from "LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression"

Related Articles

Construct:

shRNA:

Similar Products

Image Search Results